Editor - Maria Salvato | University of Maryland Medical Center | 15362
ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Maria Salvato

Maria Salvato
Maria Salvato
Institute of Human Virology
University of Maryland Medical School
University of Maryland Medical Center


Maria S. Salvato received her BA at UCLA and a doctorate in Virology at UCBerkeley in 1979.  She did post-doctoral studies at UCSF on RNA Processing with Dr. Christine Guthrie. 1980 she became a Sr Scientist at the MRC- Cambridge UK, under the direction of Sydney Brenner. In 1985 she joined Michael Oldstones group at the Scripps Research Foundation where she completed the first arenavirus sequence and discovered the zinc-binding gene product of the arenaviruses.  From 1990-2000 she was a faculty member at the University of Wisconsin, Madison, where she developed a primate model for viral hemorrhagic fever. Dr. Salvato is currently a Professor at the Institute of Human Virology, University of Maryland Medical School. She has been active on NIH study sections, has chaired the ICTV-Arenavirus Group from 2000-2011, and has served on an Institute of Medicine panel on Smallpox.

Research Interest

The Salvato laboratory investigates virus-host interactions using animal models, genomic profiling, and basic molecular virology. Recent studies explored arenavirus pathogenesis using non-human primate models for Lassa fever. Lassa fever vaccine research, has resulted in two live-attenuated candidates: one (ML29) is a reassortant between Lassa virus and Mopeia virus, and the other (YF/LAS) is a recombinant between the Yellow Fever vaccine (YF17D) and the Lassa glycoprotein. The ML29 candidate is broadly cross-reactive and protects primates from Lassa fever. The YF/LAS is effective in protecting guinea pigs but not primates. Current studies explore adjuvants to DNA vaccination that require Treg suppression.